


## CLAIMS

We claim:

1. A compound having the following structure:



or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

wherein:

A is  $-(CR_{3a}R_{3b})_nNR_1R_2$  or  $R_5$ ;

Y is  $-(CR_{3a}R_{3b})_nNR_1R_2$ ,  $R_4$ , or  $R_5$ ;

with the proviso that one of A or Y, but not both, is  $-(CR_{3a}R_{3b})_nNR_1R_2$ ;

B is  $R_4$  or  $-X-R_5$ ;

X is O, S or a bond;

$n$  is 2, 3 or 4;

$R_1$  and  $R_2$  are the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(R_8)(=NR_9)$  or  $-C(NR_6R_7)(=NR_9)$ ;

or  $R_1$  and  $R_2$  taken together with the nitrogen atom to which they are attached form a heterocycle or a substituted heterocycle;

$R_{3a}$  and  $R_{3b}$  are the same or different and, at each occurrence, independently hydrogen, alkyl, substituted alkyl, alkoxy, alkylthio, alkylamino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-COOR_{10}$  or  $-CONR_6R_7$ ;

or  $R_{3a}$  and  $R_{3b}$  taken together with the carbon atom to which they are attached form a homocycle, substituted homocycle, heterocycle or substituted heterocycle;

or  $R_{3a}$  and the carbon to which it is attached taken together with  $R_1$  and the nitrogen to which it is attached form a heterocycle or substituted heterocycle;

$R_4$  is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl;

$R_5$  is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

$R_6$  and  $R_7$  are the same or different independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

$R_8$  is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

$R_9$  is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

and

$R_{10}$  is hydrogen, alkyl, or substituted alkyl.

2. The compound of claim 1 wherein A is  $-(CR_{3a}R_{3b})_nNR_1R_2$ .
3. The compound of claim 1 wherein Y is  $-(CR_{3a}R_{3b})_nNR_1R$ .
4. The compound of claim 1 wherein B is  $-X-R_5$ .
5. The compound of claim 4 wherein X is a direct bond.
6. The compound of claim 4 where X is  $-O$  or  $-S-$ .
7. The compound of claim 1 wherein  $R_1$  is hydrogen, alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, heterocyclealkyl or substituted heterocyclealkyl.

8. The compound of claim 1 wherein  $R_4$  is substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl.

9. The compound of claim 1 wherein  $R_5$  is substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl.

10. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

11. A method for antagonizing gonadotropin-releasing hormone in a subject in need thereof, comprising administering to the subject an effective amount of a compound of claim 1.

12. A method for treating a sex-hormone related condition of a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 10.

13. The method of claim 12 wherein the sex-hormone related condition is cancer, benign prostatic hypertrophy or myoma of the uterus.

14. The method of claim 13 wherein the cancer is prostatic cancer, uterine cancer, breast cancer or pituitary gonadotroph adenomas.

15. The method of claim 12 wherein the sex-hormone related condition is endometriosis, polycystic ovarian disease, uterine fibroids or precocious puberty.

16. A method for preventing pregnancy of a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition of claim 10.

17. A method for treating lupus erythematosus, irritable bowel syndrome, premenstrual syndrome, hirsutism, short stature or sleep disorders of a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 10.